FI116558B - Alfa-interferonin stabiilit vesiliuosformulaatiot - Google Patents

Alfa-interferonin stabiilit vesiliuosformulaatiot Download PDF

Info

Publication number
FI116558B
FI116558B FI971486A FI971486A FI116558B FI 116558 B FI116558 B FI 116558B FI 971486 A FI971486 A FI 971486A FI 971486 A FI971486 A FI 971486A FI 116558 B FI116558 B FI 116558B
Authority
FI
Finland
Prior art keywords
interferon
alpha
polysorbate
formulation
aqueous solution
Prior art date
Application number
FI971486A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI971486A (fi
FI971486A0 (fi
Inventor
Pui-Ho C Yuen
Douglas F Kline
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of FI971486A publication Critical patent/FI971486A/fi
Publication of FI971486A0 publication Critical patent/FI971486A0/fi
Application granted granted Critical
Publication of FI116558B publication Critical patent/FI116558B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
FI971486A 1994-10-11 1997-04-10 Alfa-interferonin stabiilit vesiliuosformulaatiot FI116558B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32981394 1994-10-11
US08/329,813 US5766582A (en) 1994-10-11 1994-10-11 Stable, aqueous alfa interferon solution formulations
US9512362 1995-10-10
PCT/US1995/012362 WO1996011018A1 (fr) 1994-10-11 1995-10-10 Formulations de solutions d'interferon alpha aqueuses stables

Publications (3)

Publication Number Publication Date
FI971486A FI971486A (fi) 1997-04-10
FI971486A0 FI971486A0 (fi) 1997-04-10
FI116558B true FI116558B (fi) 2005-12-30

Family

ID=23287133

Family Applications (2)

Application Number Title Priority Date Filing Date
FI971486A FI116558B (fi) 1994-10-11 1997-04-10 Alfa-interferonin stabiilit vesiliuosformulaatiot
FI20055562A FI117377B (fi) 1994-10-11 2005-10-19 Kelatointiaineen käyttö alfatyyppistä interferonia sisältävässä, stabiilissa vesiformulaatiossa

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20055562A FI117377B (fi) 1994-10-11 2005-10-19 Kelatointiaineen käyttö alfatyyppistä interferonia sisältävässä, stabiilissa vesiformulaatiossa

Country Status (25)

Country Link
US (2) US5766582A (fr)
EP (2) EP0970703B1 (fr)
JP (2) JP3978228B2 (fr)
KR (1) KR100401401B1 (fr)
CN (1) CN1102408C (fr)
AT (2) ATE194774T1 (fr)
AU (1) AU708337B2 (fr)
BR (1) BR9509313A (fr)
CA (1) CA2201749C (fr)
CZ (1) CZ296961B6 (fr)
DE (2) DE69531314T2 (fr)
DK (1) DK0777495T3 (fr)
ES (2) ES2148568T3 (fr)
FI (2) FI116558B (fr)
GR (1) GR3034619T3 (fr)
HK (1) HK1008813A1 (fr)
HU (1) HU225494B1 (fr)
NO (1) NO320604B1 (fr)
NZ (1) NZ294464A (fr)
PL (1) PL183797B1 (fr)
PT (1) PT777495E (fr)
RU (1) RU2157236C2 (fr)
SK (1) SK282949B6 (fr)
UA (1) UA42028C2 (fr)
WO (1) WO1996011018A1 (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
HU228877B1 (en) * 1998-03-26 2013-06-28 Merck Sharp & Dohme Formulations for stabilization of peg-interferon alpha conjugates and method for preparation such formulations
TWI277424B (en) 1998-05-15 2007-04-01 Schering Corp Combination therapy for eradicating detectable NCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6281337B1 (en) 1998-11-12 2001-08-28 Schering Corporation Methods for conversion of protein isoforms
SI1129111T1 (sl) 1998-11-12 2009-06-30 Schering Corp Postopki za pretvorbo interferonskih izooblik in proizvodi le-teh
US7402559B2 (en) * 1999-03-24 2008-07-22 Msh Pharma, Incorporated Composition and method of treatment for urogenital conditions
PT1043025E (pt) * 1999-04-08 2005-09-30 Schering Corp Tratamento de carcinoma da celula renal
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
PE20010027A1 (es) 1999-04-08 2001-02-05 Schering Corp Uso de interferon alfa pegilado en pacientes con melanoma
IL145816A0 (en) 1999-04-09 2002-07-25 Ortho Mcneil Pharm Inc Pharmaceutical compositions of erythropoietin
KR100399156B1 (ko) * 1999-11-19 2003-09-26 주식회사 엘지생명과학 α-인터페론의 용액제형
CN1175901C (zh) * 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
DE60019458T2 (de) * 1999-12-14 2006-02-23 Thermo BioStar, Inc., Boulder Stabilisierendes verdünnungsmittel für polypeptide und antigene
JP4536194B2 (ja) * 2000-02-17 2010-09-01 大日本住友製薬株式会社 安定な注射用製剤
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
WO2002081024A1 (fr) * 2001-04-04 2002-10-17 Alza Corporation Dispositif d'administration transdermique par electrotransport comprenant une composition de reservoir compatible antimicrobienne
WO2002083165A1 (fr) * 2001-04-10 2002-10-24 Sumitomo Pharmaceuticals Co., Ltd. Preparations stables destinees a etre injectees
LT4947B (lt) 2001-09-26 2002-08-26 Biotechnologijos Institutas Interferono alfa farmacinė kompozicija
US20050232899A1 (en) * 2002-05-31 2005-10-20 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US6830744B2 (en) * 2002-05-31 2004-12-14 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
US7585647B2 (en) 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
JP2007519422A (ja) * 2004-02-02 2007-07-19 アンブレツクス・インコーポレイテツド 修飾されたヒト四螺旋バンドルポリペプチド及びそれらの使用
CN1724567B (zh) * 2004-07-22 2010-08-18 北京三元基因工程有限公司 一种稳定的重组人干扰素α1b水溶液
JP4971160B2 (ja) 2004-08-12 2012-07-11 シェーリング コーポレイション 安定するｐｅｇ化インターフェロン処方物
US20060204474A1 (en) * 2005-02-25 2006-09-14 Coroneo Minas T Treatment of epithelial layer lesions
ES2302402B1 (es) 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
CU23432B6 (es) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
US8679472B1 (en) 2006-10-05 2014-03-25 Merck, Sharp & Dohme Corp. Crystal of human interferon alpha 2B in complex with zinc
CA2685596A1 (fr) 2007-05-02 2008-11-13 Ambrx, Inc. Polypeptides d'interferon beta modifies et leurs utilisations
US8216571B2 (en) * 2007-10-22 2012-07-10 Schering Corporation Fully human anti-VEGF antibodies and methods of using
US20110184379A1 (en) * 2008-03-27 2011-07-28 Medtronic, Inc. Method and system to define patient specific therapeutic regimens by means of pharmacokinetic and pharmacodynamic tools
MX2010013759A (es) 2008-06-13 2011-05-25 Proyecto Biomedicina Cima Sl Conjugados para la administracion de compuestos biologicamente activos.
RS56632B1 (sr) 2008-10-17 2018-03-30 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
KR101303388B1 (ko) 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
RU2014102102A (ru) 2011-06-23 2015-07-27 Дигна Байотек, С.Л. КОМПОЗИЦИЯ И КОМБИНИРОВАННЫЙ ПРЕПАРАТ ИНТЕРФЕРОНА-а5 С ИНТЕРФЕРОНОМ-а2 И СПОСОБ ЛЕЧЕНИЯ ХРОНИЧЕСКОГО ГЕПАТИТА С
BR112015009453A2 (pt) 2012-10-26 2017-07-04 Lupin Ltd composição farmacêutica estável de peg-interferona alfa-2b
JP6457484B2 (ja) 2013-04-03 2019-01-23 サノフイＳａｎｏｆｉ インスリンの長時間作用型製剤による糖尿病の治療
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
ES2524516B1 (es) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
WO2016046101A1 (fr) * 2014-09-23 2016-03-31 F. Hoffmann-La Roche Ag Formulations stables, exemptes d'alcool benzylique, d'une solution aqueuse contenant de l'interféron de type alpha
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
MA45276A (fr) * 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
RU2623050C2 (ru) * 2015-12-03 2017-06-21 Виталий Эдуардович Боровиков Раствор хондроитина сульфата для внутримышечного введения и способ его получения
KR200492470Y1 (ko) 2020-03-26 2020-10-21 사공탁 빌라 주택용 쓰레기 수거함
RU2768656C1 (ru) * 2021-09-10 2022-03-24 Илья Александрович Марков Противовирусное средство в жидкой форме и способ его приготовления
CN113797318B (zh) * 2021-10-26 2023-06-30 深圳科兴药业有限公司 一种干扰素组合物及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0082481B2 (fr) * 1981-12-23 1990-09-12 Schering Corporation Compositions stabilisées d'interféron alpha et leur préparation
JPS59176216A (ja) * 1983-03-28 1984-10-05 Sumitomo Chem Co Ltd 有用なインタ−フエロン製剤
US4680175A (en) * 1984-02-07 1987-07-14 Interferon Sciences, Inc. Interferon administration vehicles
JPS60243028A (ja) * 1984-04-28 1985-12-03 Kyowa Hakko Kogyo Co Ltd インタ−フエロンの可溶化方法
US4857316A (en) * 1984-10-03 1989-08-15 Syntex (U.S.A.) Inc. Synergistic antiviral composition
US4606917A (en) * 1984-10-03 1986-08-19 Syntex (U.S.A) Inc. Synergistic antiviral composition
JPS61277633A (ja) * 1985-05-31 1986-12-08 Toray Ind Inc インタ−フエロン組成物
US4847079A (en) * 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
EP0284249A1 (fr) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Composition lyophilisée de lymphokine
US5266310A (en) * 1987-09-17 1993-11-30 Boehringer Ingelheim International Gmbh Stabilization of therapeutically active proteins in pharmaceutical preparations
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
JP3292894B2 (ja) * 1993-05-12 2002-06-17 日本電信電話株式会社 集積化受光回路

Also Published As

Publication number Publication date
CA2201749C (fr) 1999-06-15
UA42028C2 (uk) 2001-10-15
SK43997A3 (en) 1997-10-08
PL183797B1 (pl) 2002-07-31
MX9702578A (es) 1997-07-31
WO1996011018A1 (fr) 1996-04-18
JP2006193536A (ja) 2006-07-27
FI20055562A (fi) 2005-10-19
CA2201749A1 (fr) 1996-04-18
AU708337B2 (en) 1999-08-05
HUT77287A (hu) 1998-03-30
NZ294464A (en) 1999-03-29
EP0777495A1 (fr) 1997-06-11
JPH10506912A (ja) 1998-07-07
KR100401401B1 (ko) 2004-02-18
RU2157236C2 (ru) 2000-10-10
PT777495E (pt) 2000-12-29
KR970706017A (ko) 1997-11-03
DE69518084T2 (de) 2001-03-22
NO320604B1 (no) 2005-12-27
EP0970703A1 (fr) 2000-01-12
ATE194774T1 (de) 2000-08-15
SK282949B6 (sk) 2003-01-09
AU3727995A (en) 1996-05-02
DE69531314D1 (de) 2003-08-21
DE69518084D1 (de) 2000-08-24
EP0970703B1 (fr) 2003-07-16
NO971633D0 (no) 1997-04-10
HU225494B1 (en) 2007-01-29
NO971633L (no) 1997-04-10
ES2198830T3 (es) 2004-02-01
FI971486A (fi) 1997-04-10
DE69531314T2 (de) 2004-05-13
ES2148568T3 (es) 2000-10-16
BR9509313A (pt) 1998-01-27
US5935566A (en) 1999-08-10
CN1160355A (zh) 1997-09-24
FI971486A0 (fi) 1997-04-10
ATE245033T1 (de) 2003-08-15
GR3034619T3 (en) 2001-01-31
JP3978228B2 (ja) 2007-09-19
HK1008813A1 (en) 1999-05-21
FI117377B (fi) 2006-09-29
US5766582A (en) 1998-06-16
CZ296961B6 (cs) 2006-08-16
CZ110497A3 (en) 1997-09-17
EP0777495B1 (fr) 2000-07-19
PL319603A1 (en) 1997-08-18
DK0777495T3 (da) 2000-11-06
CN1102408C (zh) 2003-03-05

Similar Documents

Publication Publication Date Title
FI116558B (fi) Alfa-interferonin stabiilit vesiliuosformulaatiot
KR100731559B1 (ko) 장기 안정화 제제
US6250469B1 (en) Formulations for protection of peg-interferon alpha conjugates
EP2097068B1 (fr) Formulations de conjugués de peg-interféron alpha
EP1066059B1 (fr) Formulations servant a proteger des conjugues de peg et d'alpha-interferon
MX2015005230A (es) Composicion farmaceutica estable de peginterferon alfa-2b.
MXPA97002578A (en) Alfa-interferonestable acu solution formulations
MXPA00007209A (en) Formulations for protection of peg-interferon alpha conjugates

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 116558

Country of ref document: FI

PC Transfer of assignment of patent

Owner name: MERCK SHARP & DOHME CORP.

MA Patent expired